Список проголосовавших за комментарий " Gapping up/down: KLIC +7%, ALL +4%, DLPH +4%, COST +3%, FB +1% and MRK +1% after earnings/SSS, MJN +26% after reports of M&A discussions; SFLY -19%, NVO -7%, DB -4%, and AZN -3.5% after earnings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance/SSS</strong>:</p><ul><li><strong>ESIO</strong> +10.4%, <strong>KLIC</strong> +6.9%</li><li><strong>WFT</strong> +6.2%, (also Weatherford and Nabors form alliance for integrated drilling solutions to oil and gas land market in the lower 48 states of the United States)</li><li><strong>CACI</strong> +5.5%, <strong>HMY</strong> +5.4%, <strong>IVAC</strong> +5.3%, <strong>NOK</strong> +4.6%, <strong>BRKS</strong> +4.3%, <strong>ACLS</strong> +4.2%, <strong>ALL</strong> +3.7%, <strong>DLPH</strong> +3.7%, <strong>TSCO</strong> +3.6%, <strong>COST</strong> +3.3%, <strong>CAVM</strong> +3.1%, <strong>PH</strong> +3.1</li><li><strong>CDNS</strong> +3%, <strong>PM</strong> +2.7%, <strong>QGEN</strong> +2.6%, <strong>LCI</strong> +2.4%, <strong>ING</strong> +2.4%, <strong>BDX</strong> +2.1%, <strong>ZUMZ</strong> +2%, (Zumiez reports January comps of +9.4% vs -4.6% year ago and -3.4% last month; sees Q4 EPS at or slightly above high end of $0.60-0.66 prior guidance vs $0.64 consensus)</li><li><strong>AFG</strong> +1.5%, <strong>IDXX</strong> +1.4%, <strong>VIRT</strong> +1.4%, <strong>EXTR</strong> +1.3%, <strong>MKSI</strong> +1.3%, <strong>BSX</strong> +1.2%, <strong>FB</strong> +1.1%, <strong>MRK</strong> +1%, <strong>SIRI</strong> +1%, <strong>KMT</strong> +0.9%, <strong>RGLD</strong> +0.8%, <strong>MMC</strong> +0.7%</li><li><strong>CNMD</strong> +0.6%, <strong>COP</strong> +0.5%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>MJN</strong> +26.3% (confirms discussions with Reckitt Benckiser (RBGLY) with respect to its proposal to acquire the outstanding shares of MJN for $90 per share)</li><li><strong>M</strong> +3.4% (NY Post report that exec might be open to possible sale)</li></ul><p><strong>Select metals/mining stocks trading higher</strong>:</p><ul><li><strong>MTL</strong> +4.5%, <strong>SSRI</strong> +3.9%, <strong>AG</strong> +3.4%, <strong>GFI</strong> +2.9%, <strong>SLW</strong> +2.4%, <strong>ABX</strong> +2.4%, <strong>GDX</strong> +2.4%, <strong>PAAS</strong> +2.4%, <strong>GG</strong> +2.4%, <strong>HL</strong> +2.3%, <strong>FSM</strong> +2.1%, <strong>NEM</strong> +2.1%, <strong>GOLD</strong> +2%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>EYES</strong> +19.7% (announces that the German Institute for the Hospital Remuneration System has renewed Status 1 (full approval) for the Epiretinal Prosthesis across 15 hospitals under the NUB1 innovation program)</li><li><strong>ETRM</strong> +6.1% (after closing at highs — up more than 30% on the day)</li><li><strong>PULM</strong> +3.5% (after surging 80% higher on Wed)</li><li><strong>SND</strong> +1.2% (prices 5.95 mln common stock offering at $17.50/share)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>ACIA</strong> +3.7% (upgraded to Overweight from Equal-Weight at Morgan Stanley)</li><li><strong>SDLP</strong> +3.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)</li><li><strong>MT</strong> +3.4% (added to Conviction Buy List at Goldman)</li><li><strong>ACHN</strong> +3.4% (initiated with a Buy at Ladenburg Thalmann)</li><li><strong>MPC</strong> +2.4% (upgraded to Buy from Neutral at UBS)</li><li><strong>X</strong> +2.3% (upgraded to Buy from Neutral at BofA/Merrill)</li><li><strong>TSO</strong> +1.9% (upgraded to Overweight from Neutral at JP Morgan)</li><li><strong>TS</strong> +1.7% (upgraded to Buy at Stifel)</li><li><strong>AA</strong> +1.4% (upgraded to Overweight from Neutral at JP Morgan)</li><li><strong>PSO</strong> +0.9% (upgraded to Neutral at Credit Suisse)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>SFLY</strong> -18.9%, (also updates strategic plan / restructuring in 2017; expects to incur 2017 restructuring charges of $15-20 million), <strong>EGOV</strong> -16.7%</li><li><strong>MLNX</strong> -13.7%, <strong>CRUS</strong> -10.9%, <strong>RL</strong> -9.9%, (also announces CEO departure; Jane Nielsen to Lead Execution of the Way Forward plan), <strong>SBH</strong> -7.9%</li><li><strong>PRXL</strong> -7.6%, <strong>NVO</strong> -7.5%, <strong>QRVO</strong> -6.9%, <strong>MTW</strong> -6.7%, <strong>LM</strong> -4.7%, <strong>DB</strong> -4.3%, <strong>XEL</strong> -4%, <strong>EW</strong> -3.9%, <strong>BBD</strong> -3.9%, <strong>KEX</strong> -3.8%, <strong>AZN</strong> -3.5%, <strong>MET</strong> -3.4%</li><li><strong>SPH</strong> -3.3%, <strong>AOS</strong> -3%, <strong>TGI</strong> -2%, <strong>SYMC</strong> -1.9%, (also announces its intention to offer $1.0 billion aggregate principal amount of senior unsecured notes due 2025)</li><li><strong>CSTM</strong> -1.8%, (also commences $625 mln offering of senior unsecured notes due 2025)</li><li><strong>AGNC</strong> -1.7%, (also announces a $750 mln at-the-market offering of common stock)</li><li><strong>IP</strong> -1.7%, <strong>VOD</strong> -1.4%, <strong>HOLX</strong> -1.2%, <strong>MDU</strong> -1.2%, <strong>EL</strong> -1.2%, <strong>CFX</strong> -1.1%, <strong>SNA</strong> -1%, <strong>NXTD</strong> -0.8%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>VNR</strong> -67.6% (files petitions for relief under chapter 11 of the U.S. Bankruptcy Code)</li><li><strong>STML</strong> -34.4% (cautious comments from biotech blogger Adam Feuerstein)</li><li><strong>AVIR</strong> -24.4% (announces top-line data from its double-blind, placebo-controlled Phase 2a study of BTA585 in adults challenged intranasally with respiratory syncytial virus; data indicate there was not a significant reduction in the primary endpoint )</li><li><strong>CVEO</strong> -18.1% (Civeo commences an underwritten public offering of 20,000,000 common shares)</li><li><strong>CBAY</strong> -13.5% (to offer and sell shares of its common stock; size not disclosed)</li><li><strong>MNKD</strong> -8.6% (lower in extend trading after filing a proxy statement for an upcoming special meeting of stockholders under which it will seek approval to effect a reverse stock split )</li><li><strong>FBP</strong> -7.4% ( commences 20 mln common stock offering — 10 mln shares by funds affiliated with Thomas H. Lee Partners and 10 mln by Oaktree Capital )</li><li><strong>CORI</strong> -3.8% (to offer shares of its common stock in an underwritten public offering)</li><li><strong>CS</strong> -2.2% (in sympathy with DB)</li><li><strong>AMAG</strong> -1.9% (announces results from its definitive PK study; Makena administered subcutaneously demonstrated bioequivalence to the IM injection)</li><li><strong>LYG</strong> -1.2% (in sympathy with DB)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>VFC</strong> -2.2% (downgraded to Neutral from Buy at Goldman)</li><li><strong>JWN</strong> -1.9% (downgraded to Sell from Neutral at Goldman)</li><li><strong>WNC</strong> -1.5% (downgraded to Neutral from Overweight at Piper Jaffray)</li><li><strong>URI</strong> -0.9% (downgraded to Hold from Buy at Argus)</li></ul>"